Advances at each stage of the device and diagnostics development process, from initial creation to manufacturing, as well as consumer demand for patient-centric approaches to devices and diagnostic tools, have led large and small life sciences companies to seek collaborative partnerships that can efficiently and effectively address the needs of their varied stakeholders. When done correctly, these partnerships can have a transformational impact on your business and ensure that you remain competitive amid this rapidly evolving landscape.
All the factors to consider when creating these partnerships—pricing, reimbursement, technology requirements and patient needs—can be daunting when structuring a licensing agreement, strategic alliance or partnering transaction. It takes an experienced team that understands both the nuances of the life sciences space and the multidimensional aspects of a successful collaboration agreement to fulfill your organization’s mission while maintaining your competitive advantage.
McDermott’s life sciences lawyers leverage the combined power of collaboration and industry understanding to provide in-depth guidance to clients in every sector of the life sciences space, integrating the knowledge and experience of lawyers from across the Firm’s many Tier 1 practices to meet clients’ needs.
Baxter BioScience, a division of Baxter International Inc., in the negotiation of a license and collaboration agreement valued at nearly $1 billion with Merrimack Pharmaceuticals for the ex-US development and commercialization of MM-398, a clinical-stage oncology candidate intended for the treatment of pancreatic cancer
Innate Pharma, a major French life sciences company, on a $1.275 billion partnership – among the largest ever in the French biotech industry – with AstraZeneca to accelerate development of Innate Pharma’s IPH2201 antibody designed to stimulate the body’s immune system to destroy cancer cells
23andMe, a privately held genomics and biotechnology company, on the legal aspects of a transaction with Genentech, whereby Genentech was given exclusive access to our client’s database of almost 1 million whole genetic sequences for the study of potential genetic targets for Parkinson’s Disease.
Servier Monde, a French pharmaceutical laboratory, on its strategic partnership with Intarcia Therapeutics to develop and commercialize ITCA 650, Intarcia’s phase 3 investigational therapy for the treatment of type 2 diabetes, outside of the United States and Japan
PharmAbcine, based in Seoul, Korea, with its exclusive license agreement with TriPhase Research and Development II Corporation involving a PharmAbcine compound potentially useful in the treatment of cancer
Seikagaku Corporation in it licensing agreement with the University of British Columbia for its recombinant means of producing limulus-derived lysates
Amunix in sponsored research and license agreements with each of Biogen Idec and Eli Lilly and Company regarding coagulation factors
Biocon in its strategic global agreement with Pfizer for biosimilar versions of insulin and analog products